KKRC
CLDI icon

Kohlberg Kravis Roberts & Co’s Calidi Biotherapeutics CLDI Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-18
Closed -$351K – 216
2022
Q2 		$351K Hold
18
– – ﹤0.01% 179
2022
Q1 		$349K Buy
18
+4
+29% +$75.6K ﹤0.01% 191
2021
Q4 		$260K Buy
+14
New +$264K ﹤0.01% 158

Other funds holding CLDI

DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
LSC
Logan Stone Capital Chicago, Illinois $473M AUM 0.79% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return

Kohlberg Kravis Roberts & Co's CLDI Position: Q3 2022 in Review

Kohlberg Kravis Roberts & Co sold out of Calidi Biotherapeutics (CLDI) in Q3 2022, closing a stake of 18 shares — an estimated $351K sold.

Kohlberg Kravis Roberts & Co first reported a position in CLDI in Q4 2021 and held it in 3 quarters. The position peaked at $351K in Q2 2022. 20 funds tracked by Wall St. Rank hold CLDI as of Q3 2022.

  • Kohlberg Kravis Roberts & Co reported no remaining Calidi Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Kohlberg Kravis Roberts & Co sold 18 Calidi Biotherapeutics shares in Q3 2022, an estimated $351K.
  • Kohlberg Kravis Roberts & Co first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 3 quarters.
  • Kohlberg Kravis Roberts & Co's Calidi Biotherapeutics position peaked at $351K in Q2 2022.
  • 20 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2022.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q3 2022, filed 14 Nov 2022.